DMD Exon-Skipping Therapy Granted FDA Priority Review, With Meaningful Functional Benefit from Muscle Protein Signal the Key Question
Z-rostudirsen aims to deliver molecular therapy deeper into muscle and secure accelerated approval based on increased dystrophin; by January 2027, the FDA will assess whether this early signal is sufficient to clear the regulatory threshold.